Основная статистика
| LEI | 549300PZYT0QC9UNJF13 |
| CIK | 1628738 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Boundless Bio, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| October 31, 2022 |
TSHA / Taysha Gene Therapies Inc / Audentes Therapeutics, Inc. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 TAYSHA GENE THERAPIES, INC. (Name of Issuer) Common Stock, par value $0.00001 (Title of Class of Securities) 877619106 (CUSIP Number) Audentes Therapeutics, Inc. 600 California Street 17th Floor San Francisco, CA 94108 Attention: President (415) 818-1005 With a copy |
|
| October 31, 2022 |
EXHIBIT 2 EXHIBIT 2 POWER OF ATTORNEY Know all by these presents, that Astellas US Holding, Inc. |
|
| October 31, 2022 |
EXHIBIT 3 EXHIBIT 3 POWER OF ATTORNEY Know all by these presents, that Audentes Therapeutics, Inc. |
|
| October 31, 2022 |
EXHIBIT 4 EXHIBIT 4 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. |
|
| October 31, 2022 |
EXHIBIT 1 EXHIBIT 1 POWER OF ATTORNEY Know all by these presents, that Astellas Pharma Inc. |
|
| February 14, 2020 |
BOLD / Audentes Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 14, 2020 |
BOLD / Audentes Therapeutics, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2020 |
BOLD / Audentes Therapeutics, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Audentes Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2019 Date of Event Which |
|
| February 11, 2020 |
BOLD / Audentes Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Audentes Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 05070R104 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| January 27, 2020 |
BOLD / Audentes Therapeutics, Inc. 15-12B - - 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-37833 Audentes Therapeutics, Inc. (Exact name of registrant as speci |
|
| January 15, 2020 |
Amended and Restated Bylaws of Audentes Therapeutics, Inc. EX-3.2 Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF AUDENTES THERAPEUTICS, INC. a Delaware Corporation (hereinafter referred to as the “Corporation”) ARTICLE I OFFICES Section 1. Registered Office. The registered office and the registered agent of the Corporation are as set forth in the Certificate of Incorporation. Section 2. Other Offices. The Corporation may also have offices at such other |
|
| January 15, 2020 |
Amended and Restated Certificate of Incorporation of Audentes Therapeutics, Inc. EX-3.1 Exhibit 3.1 SIXTH RESTATED CERTIFICATE OF INCORPORATION OF AUDENTES THERAPEUTICS, INC. * * * ARTICLE I NAME The name of the Corporation is Audentes Therapeutics, Inc. ARTICLE II REGISTERED OFFICE AND REGISTERED AGENT The address of the Corporation’s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, Wilmington, County of New Castle, Delaware 1 |
|
| January 15, 2020 |
BOLD / Audentes Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on January 15, 2020 Registration No. |
|
| January 15, 2020 |
BOLD / Audentes Therapeutics, Inc. POSASR - - POSASR POSASR As filed with the Securities and Exchange Commission on January 15, 2020 Registration No. |
|
| January 15, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2020 Audentes Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 15, 2020 |
BOLD / Audentes Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on January 15, 2020 Registration No. |
|
| January 15, 2020 |
BOLD / Audentes Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on January 15, 2020 Registration No. |
|
| January 15, 2020 |
Astellas Completes Acquisition of Audentes Therapeutics EX-99.1 Exhibit 99.1 Press Release Astellas Completes Acquisition of Audentes Therapeutics - Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas’ newly created Genetic Regulation Primary Focus - Natalie C. Holles appointed President and Chief Executive Officer of Audentes T |
|
| January 15, 2020 |
BOLD / Audentes Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on January 15, 2020 Registration No. |
|
| January 15, 2020 |
BOLD / Audentes Therapeutics, Inc. SC 14D9/A - - SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Audentes Therapeutics, Inc. (Name of Subject Company) Audentes Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.00001 per share (Title o |
|
| January 15, 2020 |
ALPMF / Astellas Pharma, Inc. SC TO-T/A - - SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect, wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Co |
|
| January 15, 2020 |
BOLD / Audentes Therapeutics, Inc. POS AM - - POS AM POS AM As filed with the Securities and Exchange Commission on January 15, 2020 Registration No. |
|
| January 15, 2020 |
BOLD / Audentes Therapeutics, Inc. POS AM - - POS AM POS AM As filed with the Securities and Exchange Commission on January 15, 2020 Registration No. |
|
| January 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 7, 2020 |
BOLD / Audentes Therapeutics, Inc. SC 14D9/A - - SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Audentes Therapeutics, Inc. (Name of Subject Company) Audentes Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.00001 per share (Title o |
|
| January 7, 2020 |
ALPMF / Astellas Pharma, Inc. SC TO-T/A - - SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect, wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Co |
|
| December 30, 2019 |
ALPMF / Astellas Pharma, Inc. SC TO-T/A - - SC TO-T/A SC TO-T/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect, wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Co |
|
| December 30, 2019 |
BOLD / Audentes Therapeutics, Inc. SC 14D9/A - - SC 14D9/A SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Audentes Therapeutics, Inc. (Name of Subject Company) Audentes Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.00001 per share (Title o |
|
| December 16, 2019 |
EX-99.(E)(15) Exhibit (e)(15) AUDENTES THERAPEUTICS, INC. TAX REIMBURSEMENT AND BONUS PLAN This Tax Reimbursement and Bonus Plan (the “Plan”) was adopted by the Compensation Committee of the Board of Directors of Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), effective as of December 10, 2019 (the “Effective Date”). 1. Purpose. The purpose of the Plan is to (a) reimburse the |
|
| December 16, 2019 |
EX-99.(E)(14) Exhibit (e)(14) November 30, 2019 Eric B. Mosbrooker Re: RETENTION AGREEMENT Dear Eric: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your continued engagement |
|
| December 16, 2019 |
Exhibit (a)(1)(K) Exhibit (a)(1)(K) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| December 16, 2019 |
Astellas Commences Tender Offer to Acquire All Outstanding Shares of Audentes Exhibit (a)(1)(L) Exhibit (a)(1)(L) Press Release Astellas Commences Tender Offer to Acquire All Outstanding Shares of Audentes TOKYO, December 16, 2019 - Astellas Pharma Inc. |
|
| December 16, 2019 |
EX-99.(d)(2) Exhibit (d)(2) October 15, 2019 CONFIDENTIAL Astellas Pharma Inc. 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan Ladies and Gentlemen: In connection with discussions between Astellas Pharma Inc. (“you”) and Audentes Therapeutics, Inc. (the “Company” and collectively with you, the “parties”) of a possible negotiated acquisition transaction (a “Transaction”), the Company may f |
|
| December 16, 2019 |
Exhibit (a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of AUDENTES THERAPEUTICS, INC. |
|
| December 16, 2019 |
EX-99.(E)(13) Exhibit (e)(13) November 30, 2019 Edward Conner, M.D. Re: RETENTION AGREEMENT Dear Ed: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your continued engagement |
|
| December 16, 2019 |
Exhibit (a)(1)(C) Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of AUDENTES THERAPEUTICS, INC. |
|
| December 16, 2019 |
BOLD / Audentes Therapeutics, Inc. SC 14D9 - - SC 14D9 SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 16, 2019 |
ALPMF / Astellas Pharma, Inc. SC TO-T - - SC TO-T SC TO-T 1 d837696dsctot.htm SC TO-T SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect, wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offer |
|
| December 16, 2019 |
Exhibit (a)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of Audentes Therapeutics, Inc. |
|
| December 16, 2019 |
Exhibit (a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of AUDENTES THERAPEUTICS, INC. |
|
| December 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2019 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 9, 2019 |
ALPMF / Astellas Pharma, Inc. SC TO-C - - SC TO-C SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Common Stock, $0.00001 |
|
| December 9, 2019 |
EX-99.1 Exhibit 99.1 Cover Document to be filed Extraordinary Report Filing to Director-General of the Kanto Local Finance Bureau Date of filing December 9, 2019 Company name (Japanese) アステラス製薬株式会社 (Asuterasu Seiyaku Kabushiki-Kaisha) Company name (English) Astellas Pharma Inc. Title and name of representative President and CEO: Kenji Yasukawa Location of head office 2-5-1, Nihonbashi-Honcho, Chuo |
|
| December 4, 2019 |
Summary Transcript of Telephone Conference Call December 3, 2019 EX-99.1 Exhibit 99.1 Summary Transcript of Telephone Conference Call December 3, 2019 Introduction Thank you for joining Astellas’ telephone conference despite your busy schedule. We are holding a conference regarding the acquisition of Audentes, announced this morning. My name is Stig Ogata from Public Relations, the moderator of this telephone conference. Let me introduce the speakers for today. |
|
| December 4, 2019 |
ALPMF / Astellas Pharma, Inc. SC TO-C - - SC TO-C SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Common Stock, $0.00001 |
|
| December 3, 2019 |
EX-99.2 Exhibit 99.2 December 3, 2019 Company Name Astellas Pharma Inc. Representative Kenji Yasukawa, President and CEO (Stock Code: 4503, Tokyo Stock Exchange First Section) (URL: https://www.astellas.com/en) Fiscal Year End March Contact for Inquiries Stig Ogata, Vice President, Corporate Communications (Tel: 03-3244-3201) Astellas Enters into Definitive Agreement to Acquire Audentes Therapeuti |
|
| December 3, 2019 |
ALPMF / Astellas Pharma, Inc. SC TO-C - - SC TO-C SC TO-C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AUDENTES THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Asilomar Acquisition Corp. an indirect wholly-owned subsidiary of Astellas Pharma Inc. (Names of Filing Persons (Offerors)) Common Stock, $0.00001 |
|
| December 3, 2019 |
EX-99.4 Exhibit 99.4 External Stakeholder Q&A General 1. What has been announced? • We have announced today that Audentes has entered into a definitive agreement to be acquired by Astellas, a global pharmaceutical company headquartered in Tokyo, Japan. Both Boards of Directors unanimously approved the planned acquisition. • Under the agreement, Astellas will acquire Audentes for $60.00 per share i |
|
| December 3, 2019 |
Retention Agreement between the Company and Matthew Patterson, dated November 30, 2019 EX-10.1 Exhibit 10.1 November 30, 2019 Matthew Patterson Re: RETENTION AGREEMENT Dear Matt: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your continued engagement during a |
|
| December 3, 2019 |
EX-99.1 Exhibit 99.1 Good afternoon team BOLD! Just a moment ago we announced the very exciting news that Audentes has entered into a definitive agreement to be acquired by Astellas, a global pharmaceutical company headquartered in Tokyo, Japan. The press release is enclosed for your reference. This news is the ultimate recognition of the phenomenal work that our team has done to make the Audentes |
|
| December 3, 2019 |
EX-99.3 Acquisition of Audentes Establishing a leading position in gene therapy Naoki Okamura Representative Director, Corporate Executive Vice President, Chief Strategy Officer and Chief Financial Officer Astellas Pharma Inc. December 3, 2019 Exhibit 99.3 This document contains “forward-looking statements” relating to the acquisition of Audentes by Astellas. Such forward-looking statements includ |
|
| December 3, 2019 |
EX-99.4 5 d599615dex994.htm EX-99.4 Exhibit 99.4 December 2, 2019 Dear Audentes Colleagues: On behalf of the more than 16,000 employees of the Astellas group worldwide, it is a great pleasure for me to share with you how excited all of us are about today’s announcement that Astellas and Audentes have reached an agreement to merge and work together in support of patients moving forward. We highly v |
|
| December 3, 2019 |
EX-99.5 Exhibit 99.5 December 2, 2019 Dear XLMTM Patient Community, I am writing to share with you some news announced earlier today, that we have entered into a definitive merger agreement with Astellas, a global pharmaceutical company headquartered in Tokyo, Japan. The press release, sharing the details of the acquisition, can be found here: https://audentestx.gcs-web.com/news-releases/news-rele |
|
| December 3, 2019 |
EX-99.2 Exhibit 99.2 December 3, 2019 Dear Astellas Colleagues, We are absolutely delighted with today’s news and excited to join together with Astellas. We have a great deal of respect and admiration for your organization, the vision and the strategy you have set, and we look forward to the opportunities that will be created by bringing our two great companies together. Audentes is a passionate a |
|
| December 3, 2019 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER DATED AS OF DECEMBER 2, 2019 AMONG ASTELLAS PHARMA INC., ASILOMAR ACQUISITION CORP. AND AUDENTES THERAPEUTICS, INC. Table of Contents Page ARTICLE 1 DEFINITIONS; INTERPRETATION 2 SECTION 1.1. Definitions 2 SECTION 1.2. Interpretation 12 ARTICLE 2 THE OFFER 13 SECTION 2.1. The Offer 13 SECTION 2.2. Company Action 15 ARTICLE 3 THE MER |
|
| December 3, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2019 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commi |
|
| December 3, 2019 |
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics EX-99.1 Exhibit 99.1 Press Release Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics • Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company • Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and manufactu |
|
| December 3, 2019 |
BOLD / Audentes Therapeutics, Inc. SC14D9C - - SC14D9C SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 Audentes Therapeutics, Inc. (Name of Subject Company) Audentes Therapeutics, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.00001 per share (Title of Class of Securitie |
|
| December 3, 2019 |
EX-99.3 Exhibit 99.3 Employee Q&A 1. What was announced today? We have announced today that Audentes has entered into a definitive agreement to be acquired by Astellas, a global pharmaceutical company headquartered in Tokyo, Japan. Both Boards of Directors unanimously approved the planned acquisition. Under the agreement, Astellas will acquire Audentes for $60.00 per share in cash representing |
|
| December 3, 2019 |
Retention Agreement between the Company and Natalie Holles, dated November 30, 2019 EX-10.2 4 d841784dex102.htm EX-10.2 Exhibit 10.2 November 30, 2019 Natalie Holles Re: RETENTION AGREEMENT Dear Natalie: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your co |
|
| December 3, 2019 |
Template Email to partners/vendors EX-99.6 Exhibit 99.6 Template Email to partners/vendors Template cover email for communications to other partners/vendors: Dear [xxx], I am writing to share with you some news announced earlier today, that we have entered into a definitive agreement for Astellas to acquire Audentes. The press release, sharing the details of the acquisition, can be found here: https://audentestx.gcs-web.com/news-re |
|
| December 3, 2019 |
Retention Agreement between the Company and Thomas Soloway, dated November 30, 2019 EX-10.3 Exhibit 10.3 November 30, 2019 Thomas Soloway Re: RETENTION AGREEMENT Dear Tom: As you know, Astellas Pharma Inc. (“Parent”), through a subsidiary, intends to acquire Audentes Therapeutics, Inc. (the “Company”) pursuant to an Agreement and Plan of Merger among Parent, the Company and the other parties thereto (the “Merger Agreement”). We believe that your continued engagement during a rete |
|
| December 3, 2019 |
Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics EX-99.1 Exhibit 99.1 Press Release Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics • Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company • Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and manufactu |
|
| December 3, 2019 |
Evolving how we create VALUE with the acquisition of Audentes EX-99.5 Exhibit 99.5 Evolving how we create VALUE with the acquisition of Audentes Dear Astellas Colleagues: I am very pleased to announce that Astellas and Audentes Therapeutics, Inc., an innovative biotechnology company located in San Francisco, California, have entered into an agreement for Astellas to acquire Audentes. The addition of Audentes’ talent and exciting clinical pipeline of gene the |
|
| November 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Juris |
|
| November 7, 2019 |
EX-99.1 2 bold20191107ex991.htm EXHIBIT 99.1 Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update - BLA submission for AT132 for the treatment of XLMTM on-track for mid-2020; MAA on-track for second half of 2020 - Continued progress in Pompe Disease, DMD and DM1 pipeline programs: AT845 IND submitted and clinical start-up activities underway; AT702 IND o |
|
| November 7, 2019 |
2018 Equity Inducement forms of award agreements Exhibit 10.3 AUDENTES THERAPEUTICS, INC. 2018 EQUITY INDUCEMENT PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD GRANT NUMBER: Unless otherwise defined herein, the terms defined in the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of this Notice of Restricted Stock Unit Awar |
|
| November 7, 2019 |
Exhibit 10.1 AUDENTES THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Com |
|
| November 7, 2019 |
2016 Equity Incentive forms of award agreements Exhibit 10.2 AUDENTES THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD GRANT NUMBER: Unless otherwise defined herein, the terms defined in the Audentes Therapeutics, Inc. 2016 Equity Incentive Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of this Notice of Restricted Stock Unit Award |
|
| November 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37 |
|
| October 9, 2019 |
EX-99.2 12 exhibit992.htm EXHIBIT 99.2 Exhibit 99.2 The ASPIRO Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Safety and Efficacy Findings James J. Dowling, MD, PhD Associate Professor of Molecular Genetics University of Toronto Perry B. Shieh, Nancy Kuntz, Carsten G. Bönnemann, Wolfgang Müller-Felber, Michael W. Lawlor, Laurent Servais, Barbara Smith, Mo Noursal |
|
| October 9, 2019 |
EX-99.1 8 exhibit991.htm EXHIBIT 99.1 Exhibit 99.1 Audentes Therapeutics Presents New Positive Data from ASPIRO, the Clinical Trial Evaluating AT132 in Patients with X-Linked Myotubular Myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society - First seven treated patients now ventilator independent and able to rise to a standing position or walk - Continued signific |
|
| October 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisd |
|
| September 16, 2019 |
BOLD / Audentes Therapeutics, Inc. / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Amendment No )* Under the Securities Exchange Act of 1934 Audentes Therapeutics, Inc. (Name of Issuer) Common Shares, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) September 4, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| August 23, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K/A ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdi |
|
| August 7, 2019 |
Separation Letter Agreement, executed May 30, 2019, by and between the Registrant and John Gray Exhibit 10.1 [Audentes Letterhead] May 24, 2019 John Gray, Ph.D. Re: Terms of Separation Dear John: This letter agreement (this “Agreement”) confirms the agreement between you and Audentes Therapeutics, Inc. (the “Company”) concerning the terms of your separation from the Company and offers you the separation compensation specified herein in exchange for your general release of claims, covenant no |
|
| August 7, 2019 |
Separation Letter Agreement, executed June 25, 2019, by and between the Registrant and Suyash Prasad Exhibit 10.2 [Audentes Letterhead] June 24, 2019 Dr. Suyash Prasad Re: Terms of Separation Dear Suyash: This letter agreement (this “Agreement”) confirms the agreement between you and Audentes Therapeutics, Inc. (the “Company”) concerning the terms of your separation from the Company and offers you the separation compensation specified herein in exchange for your general release of claims, covenan |
|
| August 7, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 A |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 q219epr-8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-160617 |
|
| August 6, 2019 |
a20190806q22019eprfinal Audentes Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Commenced enrollment of 8 patients into an ASPIRO pivotal expansion cohort to confirm the safety and efficacy profile of AT132 for the treatment of X-linked myotubular myopathy (XLMTM) at dose of 3x1014 vg/kg - Biologics License Application (BLA) submission for AT132 planned |
|
| June 28, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdic |
|
| June 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdict |
|
| May 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdict |
|
| May 10, 2019 |
BOLD / Audentes Therapeutics, Inc. S-8 S-8 As filed with the Securities and Exchange Commission on May 10, 2019 Registration No. |
|
| May 8, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ——————— FORM 8-K ——————— CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 ——————— Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) ——————— Delaware 001-37833 46-1606174 (State or Other Jurisdicti |
|
| May 7, 2019 |
EX-99.1 2 ex991q12019eprfinal.htm EXHIBIT 99.1 Exhibit 99.1 Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update ‐ Recently presented positive new data from ASPIRO, the Phase 1/2 study of AT132 for treatment of XLMTM ‐ On track to submit updated ASPIRO data package with optimal dose selection to FDA in the second quarter of 2019 and to provide update on |
|
| May 1, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2019 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commission |
|
| May 1, 2019 |
ASPIRO Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Safety and Efficacy Findings Perry Shieh, MD PhD Associate Professor of Neurology, University of California Los Angeles Exhibit 99. |
|
| May 1, 2019 |
EX-99.1 2 bold-ex9916.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy - New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2 - Signi |
|
| April 26, 2019 |
BOLD / Audentes Therapeutics, Inc. DEFA14A DEFA14A NOTICE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 26, 2019 |
BOLD / Audentes Therapeutics, Inc. DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 8, 2019 |
EX-99.1 2 bold-ex9916.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy - Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) a |
|
| April 8, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2019 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commissi |
|
| March 1, 2019 |
BOLD / Audentes Therapeutics, Inc. 10-K (Annual Report) i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37833 Audentes Therapeutics, I |
|
| March 1, 2019 |
Form of Restricted Stock Unit Award Agreement for 2018 Equity Inducement Plan. EX-10.5B 2 bold-ex105b144.htm EX-10.5B Exhibit 10.5b AUDENTES THERAPEUTICS, INC. 2018 Equity INDUCEMENT Plan NOTICE OF RESTRICTED STOCK UNIT AWARD GRANT NUMBER: Unless otherwise defined herein, the terms defined in the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan (the “Plan”) will have the same meanings in this Notice of Restricted Stock Unit Award and the electronic representation of t |
|
| February 27, 2019 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2019 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 27, 2019 |
Exhibit 99.1 Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update On track to select optimal dose of AT132 for the treatment of XLMTM in the second quarter of 2019, and gain final agreement on BLA and MAA submission pathways in the third quarter of 2019 On track to submit an Investigational New Drug (IND) application for AT845 for Pompe Di |
|
| February 14, 2019 |
BOLD / Audentes Therapeutics, Inc. / Redmile Group, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Audentes Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2018 Date of Event Which |
|
| February 14, 2019 |
EX-99.1 2 tv513365ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.00001 pa |
|
| February 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2019 |
BOLD / Audentes Therapeutics, Inc. / 5AM VENTURES III, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number |
|
| February 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 7, 2018 |
BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2018 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Thera |
|
| November 7, 2018 |
Net Commercial Lease, dated August 15, 2018, by and between the Registrant and JCN Partners. Exhibit 10.1 NET COMMERCIAL LEASE This Net Commercial Lease (this “Lease”) dated August 15, 2018, for reference purposes only, is by and between JCN PARTNERS, a California limited partnership (“Lessor”), and AUDENTES THERAPEUTICS, INC., a Delaware corporation (“Lessee”). IT IS HEREBY AGREED: Lessor hereby leases to Lessee, and Lessee hereby leases from Lessor, the premises described in Paragraph 1 |
|
| November 7, 2018 |
EX-10.2 3 bold-ex102120.htm EX-10.2 Exhibit 10.2 FIRST AMENDMENT TO NET COMMERCIAL LEASE This First Amendment to Net Commercial Lease (this “Amendment”) dated September 30, 2018, for reference purposes only, is by and between JCN PARTNERS, a California limited partnership (“Lessor”), and AUDENTES THERAPEUTICS, INC., a Delaware corporation (“Lessee”), with reference to the following facts: WHEREAS, |
|
| November 7, 2018 |
Exhibit 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into between Audentes Therapeutics, Inc. (the “Company”) and Natalie Holles (the “Executive”). This Agreement is effective as of September , 2018 (the “Effective Date”). This Agreement supersedes and replaces in its entirety the Executive Employment Agreements dated February 14, 2018 and Ju |
|
| November 6, 2018 |
BOLD / Audentes Therapeutics, Inc. S-8 S-8 1 bold-s8.htm S-8 As filed with the Securities and Exchange Commission on November 6, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AUDENTES THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-1606174 (State or other jurisdiction of (I.R.S. Emp |
|
| November 6, 2018 |
2018 Equity Inducement Plan and forms of award agreements. Exhibit 99.2 Audentes Therapeutics, INC. 2018 EQUITY InDUCEMENT PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Co |
|
| November 6, 2018 |
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update EX-99.1 2 bold-ex9916.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update - Completed Cohort 2 enrollment in ASPIRO, the Phase 1/2 clinical study of AT132 for the treatment of X-linked Myotubular Myopathy - Plan interactions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in Q4 2018 to di |
|
| November 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2018 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 29, 2018 |
BOLD / Audentes Therapeutics, Inc. / Partner Fund Management, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number) October 17, 2018 Date of Event Which Req |
|
| October 29, 2018 |
EX-99.1 2 tv505647ex99-1.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Audentes Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exch |
|
| October 11, 2018 |
Audentes Therapeutics Announces Pricing of Public Offering of Common Stock EX-99.1 4 bold-ex9917.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Announces Pricing of Public Offering of Common Stock SAN FRANCISCO, Oct. 10, 2018 / PRNewswire/ - Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the |
|
| October 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commis |
|
| October 11, 2018 |
1.1Underwriting Agreement dated October 10, 2018 Exhibit 1.1 Audentes Therapeutics, Inc. (a Delaware corporation) 5,200,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: October 10, 2018 Audentes Therapeutics, Inc. (a Delaware corporation) 5,200,000 Shares of Common Stock UNDERWRITING AGREEMENT October 10, 2018 Merrill Lynch, Pierce, Fenner & Smith Incorporated J.P.Morgan Securities LLC Cowen and Company, LLC as Representatives of the sev |
|
| October 11, 2018 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-224020 CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered Amount to be registered(1) Proposed maximum offering price per share Proposed maximum aggregate offering price Amount of registration fee(2) Common stock, $0.00001 par value per share 5,980,000 $29.00 $173,420,000 $21,018.50 (1) Inc |
|
| October 9, 2018 |
Subject to Completion Preliminary Prospectus Supplement dated October 9, 2018 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-224020 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitt |
|
| October 5, 2018 |
EX-99.1 2 bold-ex9916.htm EX-99.1 ASPIRO Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Preliminary Safety and Efficacy Findings Exhibit 99.1 Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainti |
|
| October 5, 2018 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commis |
|
| August 10, 2018 |
BOLD / Audentes Therapeutics, Inc. 10-K/A (Annual Report) 10-K/A 1 bold-10ka20171231.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIO |
|
| August 10, 2018 |
BOLD / Audentes Therapeutics, Inc. CORRESP August 10, 2018 Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549-3720 Re: Audentes Therapeutics, Inc. |
|
| August 10, 2018 |
BOLD / Audentes Therapeutics, Inc. 10-Q/A (Quarterly Report) 10-Q/A 1 bold-10qa20180331.htm 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from |
|
| August 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2018 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 7, 2018 |
EX-99.1 2 bold-ex9916.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Reports Second Quarter 2018 Financial Results and Provides Update on ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy - Muscle biopsy data demonstrate highly efficient tissue transduction as indicated by vector copy number, robust myotubularin protein expression as assessed by western bl |
|
| August 7, 2018 |
BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2018 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Therapeuti |
|
| June 8, 2018 |
BOLD / Audentes Therapeutics, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commissio |
|
| May 16, 2018 |
EX-99.2 3 bold-ex9926.htm EX-99.2 X-Linked Myotubular Myopathy (XLMTM) ASPIRO Phase 1/2 Gene Therapy Trial In XLMTM: Interim Safety And Efficacy Findings Exhibit 99.2 Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assump |
|
| May 16, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commissio |
|
| May 16, 2018 |
Exhibit 99.1 Audentes Announces Continuing Positive Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy - Significant improvements in neuromuscular and respiratory function at 24-week timepoint - Encouraging initial efficacy observed at four-week timepoint in Cohort 1 expansion patients - Patient 1 has achieved ventilator indepen |
|
| May 10, 2018 |
BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2018 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Therapeut |
|
| May 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2018 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2018 |
Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update Exhibit 99.1 Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update - Completed dosing of three additional patients as an expansion of the first dose cohort of ASPIRO, the Phase 1/2 clinical study of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM) - Plan to report additional interim data from ASPIRO during an oral presentation at the 21st A |
|
| May 8, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commis |
|
| April 27, 2018 |
BOLD / Audentes Therapeutics, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 27, 2018 |
BOLD / Audentes Therapeutics, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 29, 2018 |
EX-4.5 4 d556584dex45.htm EX-4.5 Exhibit 4.5 AUDENTES THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 3 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS |
|
| March 29, 2018 |
EX-1.2 2 d556584dex12.htm EX-1.2 Exhibit 1.2 AUDENTES THERAPEUTICS, INC. $150,000,000 COMMON STOCK SALES AGREEMENT March 29, 2018 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Audentes Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of |
|
| March 29, 2018 |
BOLD / Audentes Therapeutics, Inc. S-3ASR S-3ASR 1 d556584ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 29, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Audentes Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 46-1606174 (State or other |
|
| March 29, 2018 |
EX-4.4 3 d556584dex44.htm EX-4.4 Exhibit 4.4 FORM OF DEBT SECURITY [Face of Security] AUDENTES THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF I |
|
| March 29, 2018 |
Statement of Computation of Ratio of Earnings to Fixed Charges EX-12.1 Exhibit 12.1 AUDENTES THERAPEUTICS, INC. Computation of Ratio of Earnings to Fixed Charges Year Ended December 31, 2013 2014 2015 2016 2017 (in thousands) Earnings before fixed charges: Net loss $ (3,054 ) $ (10,819 ) $ (26,458 ) $ (59,668 ) $ (90,238 ) Fixed charges: Estimated interest expense within rental expense $ 10 $ 84 $ 490 $ 852 $ 986 Deficiency of earnings: $ (3,064 ) $ (10,904 ) |
|
| March 9, 2018 |
Power of Attorney. (See signature page thereto.) i UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37833 Audentes Ther |
|
| March 9, 2018 |
EX-10.24 4 bold-ex1024122.htm EX-10.24 EXHIBIT 10.24 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. FOURTH AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT This FOURTH AMENDMENT (“Fourth Amendmen |
|
| March 9, 2018 |
Form of Executive Employment Agreement Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into between Audentes Therapeutics, Inc. (the “Company”) and (the “Executive”). This Agreement is effective as of , 20 (the “Effective Date”). [This Agreement supersedes and replaces in its entirety the dated , between Executive and the Company.]1 In consideration of the promises and the te |
|
| March 9, 2018 |
EXHIBIT 10.18 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. FIRST AMENDMENT TO License Agreement This FIRST AMENDMENT TO LICENSE AGREEMENT (“First Amendment”) is entered into as of November 3, 2017 (“Firs |
|
| March 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2018 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 8, 2018 |
EX-99.1 2 bold-ex99117.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Reports Fourth Quarter 2017 and Full Year Financial Results and Provides Corporate Update - Announced positive interim data in the first three patients dosed in ASPIRO, the Phase 1/2 clinical study of AT132 to treat X-Linked Myotubular Myopathy (XLMTM). Plan to dose three additional patients in the first cohort of ASPIRO and to |
|
| February 14, 2018 |
BOLD / Audentes Therapeutics, Inc. / Flynn James E Passive Investment SC 13G/A 1 e617661sc13ga-audentes.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3) * Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities |
|
| February 14, 2018 |
SC 13G/A 1 tv485881sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No.1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) |
|
| February 13, 2018 |
BOLD / Audentes Therapeutics, Inc. / ORBIMED ADVISORS LLC - 13G/A (Passive Investment) SC 13G/A 1 bold123117a1.htm 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 13, 2018 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant t |
|
| February 13, 2018 |
BOLD / Audentes Therapeutics, Inc. / Versant Side Fund IV, L.P. - SC 13G/A Passive Investment SC 13G/A 1 a18-59241sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CU |
|
| February 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) January 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 8, 2018 |
BOLD / Audentes Therapeutics, Inc. / 5AM VENTURES III, L.P. - SC 13G/A (Passive Investment) SC 13G/A 1 a18-56242sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Clas |
|
| January 25, 2018 |
Audentes Therapeutics Announces Pricing of Public Offering of Common Stock Exhibit 99.1 Audentes Therapeutics Announces Pricing of Public Offering of Common Stock SAN FRANCISCO, Jan. 24, 2018 / PRNewswire/ ? Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its underwritten public |
|
| January 25, 2018 |
Underwriting Agreement dated January 24, 2018 EX-1.1 2 d530511dex11.htm EX-1.1 Exhibit 1.1 AUDENTES THERAPEUTICS, INC. (a Delaware corporation) 5,750,000 Shares of Common Stock UNDERWRITING AGREEMENT Dated: January 24, 2018 AUDENTES THERAPEUTICS, INC. (a Delaware corporation) 5,750,000 Shares of Common Stock UNDERWRITING AGREEMENT January 24, 2018 Merrill Lynch, Pierce, Fenner & Smith Incorporated Cowen and Company, LLC Leerink Partners LLC a |
|
| January 25, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37833 46-1606174 (State or other jurisdiction of incorporation) (Commi |
|
| January 25, 2018 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-219797 PROSPECTUS SUPPLEMENT (To prospectus dated August 23, 2017) 5,750,000 Shares Common Stock We are offering 5,750,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol ?BOLD.? The last reported sale price of our common stock on The Nasdaq Global Market on January 24, |
|
| January 24, 2018 |
BOLD / Audentes Therapeutics, Inc. S-3MEF S-3MEF As filed with the Securities and Exchange Commission on January 24, 2018 Registration No. |
|
| January 23, 2018 |
BOLD / Audentes Therapeutics, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (C |
|
| January 23, 2018 |
Subject to Completion Preliminary Prospectus Supplement dated January 23, 2018 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-219797 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. Su |
|
| January 4, 2018 |
BOLD / Audentes Therapeutics, Inc. 8-K (Current Report) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2018 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Co |
|
| January 4, 2018 |
EX-99.1 2 d710862dex991.htm EX-99.1 Exhibit 99.1 Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy - Significant improvements in neuromuscular function as assessed by the CHOP-INTEND scale - Significant improvements in respiratory function as assessed by maximal inspiratory pressure (MIP) - M |
|
| January 4, 2018 |
EX-99.2 ASPIRO Study Interim data as of December 21, 2017 Exhibit 99.2 Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual act |
|
| December 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commi |
|
| November 17, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 ( |
|
| November 14, 2017 |
BOLD / Audentes Therapeutics, Inc. S-8 bold-s8.htm As filed with the Securities and Exchange Commission on November 14, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AUDENTES THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 46-1606174 (State or other jurisdiction of (I.R.S. Employer inc |
|
| November 14, 2017 |
BOLD / Audentes Therapeutics, Inc. 8-K (Current Report) bold-8k20171114.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of |
|
| November 14, 2017 |
Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update bold-ex9918.htm Exhibit 99.1 Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update - Completed enrollment of the first dose cohort of ASPIRO, the Phase 1/2 clinical study of AT132 to treat X-Linked Myotubular Myopathy (XLMTM) - AT132 has been well-tolerated by all patients with no significant treatment-related safety signals to date - Plan to report preli |
|
| November 14, 2017 |
BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2017 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Thera |
|
| September 27, 2017 |
bold-ex993798.pptx.htm AT132 for X-Linked Myotubular Myopathy INCEPTUS Study Interim Results Exhibit 99.3 CONFIDENTIAL Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances t |
|
| September 27, 2017 |
bold-ex994487.pptx.htm Audentes Corporate Overview September 27, 2017 Exhibit 99.4 Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual act |
|
| September 27, 2017 |
EX-99.1 2 bold-ex991488.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy Preliminary data from ASPIRO expected to be available in the fourth quarter of 2017 SAN FRANCISCO, Sept. 21, 2017 / PRNewswire/ - Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company |
|
| September 27, 2017 |
Audentes Therapeutics 8-K (Current Report/Significant Event) bold-8k20170921.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of |
|
| September 27, 2017 |
bold-ex992639.htm Exhibit 99.2 Audentes Therapeutics Announces Rare Pediatric Disease and Fast Track Designations for AT132 for the Treatment of X-Linked Myotubular Myopathy Preliminary data from ASPIRO, the Phase 1/2 study of AT132, expected to be available in the fourth quarter of 2017 SAN FRANCISCO, September 27, 2017 / PRNewswire/ - Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology c |
|
| August 22, 2017 |
AUDENTES THERAPEUTICS, INC. 600 California Street, 17th Floor San Francisco, California 94108 August 22, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jeffrey Gabor Re: Audentes Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-219797) filed August 8, 2017 Ladies and Gentlemen: Re |
|
| August 10, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bold-8k20170810.htm EARNINGS RELEASE 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State |
|
| August 10, 2017 |
Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update bold-ex99115.htm Exhibit 99.1 Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update - Audentes plans to initiate Phase 1/2 clinical trials for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) and AT342 to treat Crigler-Najjar Syndrome in the third quarter of 2017 - Audentes plans to report preliminary clinical data from Phase 1/2 studies of AT132 and |
|
| August 10, 2017 |
Exhibit 10.3 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. THIRD AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT This THIRD AMENDMENT (“Third Amendment”) is entered into as of July 14, 2017 (th |
|
| August 10, 2017 |
Exhibit 10.1 BRITANNIA GATEWAY BUSINESS PARK LEASE This Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between BRITANNIA GATEWAY II LIMITED PARTNERSHIP, a Delaware limited partnership ("Landlord"), and AUDENTES THERAPEUTICS, INC., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION |
|
| August 10, 2017 |
BOLD / Audentes Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2017 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Therapeuti |
|
| August 10, 2017 |
Exhibit 10.2 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (“Agreement”) is effective as of September 26, 2014 (the “Effe |
|
| August 8, 2017 |
S-3 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2017 Registration No. |
|
| August 8, 2017 |
EX-4.5 Exhibit 4.5 AUDENTES THERAPEUTICS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 - DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 3 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 - THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 |
|
| August 8, 2017 |
EX-12.1 Exhibit 12.1 AUDENTES THERAPEUTICS, INC. Computation of Ratio of Earnings to Fixed Charges Year Ended December 31, Three Months Ended March 31, 2017 2013 2014 2015 2016 (in thousands) Earnings before fixed charges: Net loss $ (3,054 ) $ (10,819 ) $ (26,458 ) $ (59,668 ) $ (18,115 ) Fixed charges: Estimated interest expense within rental expense $ 10 $ 84 $ 490 $ 852 $ 233 Deficiency of ear |
|
| August 8, 2017 |
EX-4.4 3 d436569dex44.htm EX-4.4 Exhibit 4.4 FORM OF DEBT SECURITY [Face of Security] AUDENTES THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF I |
|
| August 8, 2017 |
AUDENTES THERAPEUTICS, INC. COMMON STOCK SALES AGREEMENT EX-1.2 Exhibit 1.2 AUDENTES THERAPEUTICS, INC. $75,000,000 COMMON STOCK SALES AGREEMENT August 8, 2017 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Audentes Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees |
|
| July 14, 2017 |
bold-8k20170712.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Inco |
|
| June 13, 2017 |
Audentes Therapeutics 8-K - JENNIFER JARRETT DIRECTOR APPOINTMENT (Current Report/Significant Event) bold-8k20170612.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Inco |
|
| June 7, 2017 |
Audentes Therapeutics 8-K (Current Report/Significant Event) bold-8k20170607.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incor |
|
| May 11, 2017 |
Audentes Therapeutics 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2017 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Therapeut |
|
| May 11, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition bold-8k20170511.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Incor |
|
| May 11, 2017 |
Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update bold-ex99142.htm Exhibit 99.1 Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update - INDs for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) and AT342 to treat Crigler-Najjar Syndrome are active - Strengthened balance sheet with a follow-on financing of $80.7 million in net proceeds - Preliminary clinical data from phase 1/2 studies of AT132 and AT3 |
|
| May 5, 2017 |
Audentes Therapeutics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Commis |
|
| May 5, 2017 |
EXECUTIVE EMPLOYMENT AGREEMENT EX-10.01 2 d387386dex1001.htm EX-10.01 Exhibit 10.01 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into between Audentes Therapeutics, Inc. (the “Company”) and (the “Executive”). This Agreement is effective as of , 20 (the “Effective Date”). [This Agreement supersedes and replaces in its entirety the dated , between Executive and the Company.]1 In |
|
| April 27, 2017 |
bold-defa14a20170427.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission |
|
| April 27, 2017 |
bold-def14a20170427.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission |
|
| April 27, 2017 |
Audentes Therapeutics AUDENTES THERAPEUTICS, INC. (Passive Acquisition of More Than 5% of Shares) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 05070R104 (CUSIP Number) April 18, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| April 26, 2017 |
BOLD / Audentes Therapeutics, Inc. / Flynn James E Passive Investment SC 13G/A 1 e616075sc13ga-at.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 0507 |
|
| April 19, 2017 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-217225 and 333-217365 PROSPECTUS 5,200,000 Shares Common Stock We are offering 5,200,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol ?BOLD.? The last reported sale price of our common stock on The NASDAQ Global Market on April 18, 2017 was $15.19 per share. We are |
|
| April 18, 2017 |
S-1MEF 1 d357125ds1mef.htm S-1MEF As filed with the Securities and Exchange Commission on April 18, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Audentes Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 46-1606174 (State or other jurisdiction o |
|
| April 17, 2017 |
EX-1.1 2 d307713dex11.htm FORM OF UNDERWRITING AGREEMENT Exhibit 1.1 AUDENTES THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT Dated: April [•], 2017 AUDENTES THERAPEUTICS, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENT April [•], 2017 Merrill Lynch, Pierce, Fenner & Smith Incorporated Cowen and Company, LLC Piper Jaffra |
|
| April 17, 2017 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on April 17, 2017 Registration No. |
|
| April 17, 2017 |
BOLD / Audentes Therapeutics, Inc. ESP CORRESP April 17, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 17, 2017 |
BOLD / Audentes Therapeutics, Inc. ESP CORRESP 1 filename1.htm AUDENTES THERAPEUTICS, INC. 600 California Street, 17th Floor San Francisco, California 94108 April 17, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Dorrie Yale Re: Audentes Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-217225) originally filed April 1 |
|
| April 10, 2017 |
EX-10.6 2 d307713dex106.htm OFFER LETTER AGREEMENT Exhibit 10.6 August 18, 2015 (As Revised) VIA Email Dear Tom, I am very pleased to extend an offer to join Audentes Therapeutics. We believe your experience, talent, and passion will make you a wonderful addition to our team. The following outlines the terms of our offer. Position • Senior Vice President, Chief Financial Officer. This position is |
|
| April 10, 2017 |
S-1 1 d307713ds1.htm S-1 Table of Contents As filed with the Securities and Exchange Commission on April 10, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2836 46-1606174 (State or other jur |
|
| April 10, 2017 |
Offer Letter Agreement Exhibit 10.7 July 21, 2015 (As revised) VIA Email Dear Natalie, I am very pleased to extend an offer to join Audentes Therapeutics. We believe your experience, talent, and passion will make you a wonderful addition to our team. The following outlines the terms of our offer. Position ? Senior Vice President, Chief Operating Officer. This position is considered an exempt posit |
|
| April 3, 2017 |
Audentes Therapeutics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Comm |
|
| April 3, 2017 |
EX-10.01 2 d270046dex1001.htm EX-10.01 EXHIBIT 10.01 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. SECOND AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT THIS SECOND AMENDMENT (“Second Amendmen |
|
| March 13, 2017 |
Exhibit 10.15 FIRST AMENDMENT TO OFFICE LEASE This FIRST AMENDMENT TO OFFICE LEASE (the “Amendment”) dated as of November 22, 2016 (the “Amendment Date”) is by and between MEPT 600 California Street LLC, a Delaware limited liability company (“Landlord”) and Audentes Therapeutics, Inc., a Delaware corporation (“Tenant”). BACKGROUND A. Landlord and Tenant entered into that certain Office Lease dated |
|
| March 13, 2017 |
EX-10.13 5 bold-ex1013741.htm EX-10.13 Exhibit 10.13 FIRST AMENDMENT TO LEASE AGREEMENT Property Address: 550-3 Eccles Avenue South San Francisco, California This First Amendment to Lease Agreement (this “Amendment”), dated for reference purposes January 13, 2017, is incorporated into and made a part of that certain Net Commercial Lease agreement (“Lease Agreement”) dated January 7, 2017 between 5 |
|
| March 13, 2017 |
EXHIBIT 10.24 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. FIRST AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT THIS FIRST AMENDMENT (“First Amendment”) is entered into as of December 21, 201 |
|
| March 13, 2017 |
Exhibit 10.12 NET COMMERCIAL LEASE This Lease dated January 7, 2017, for reference purposes only, is by and between 546 ECCLES AVENUE, A CALIFORNIA LIMITED PARTNERSHIP (“Lessor”) and Audentes Therapeutics, Inc., a Delaware corporation (“Lessee”). IT IS HEREBY AGREED: Lessor hereby leases to Lessee, and Lessee hereby leases from Lessor, the premises described in Paragraph 1 below for the term and s |
|
| March 13, 2017 |
Net Commercial Lease, effective June 1, 2017, by and between the Registrant and JCN Partners EX-10.11 3 bold-ex10111123.htm EX-10.11 Exhibit 10.11 NET COMMERCIAL LEASE This Lease dated January 7, 2017, for reference purposes only, is by and between JCN PARTNERS, A CALIFORNIA LIMITED PARTNERSHIP (“Lessor”) and AUDENTES THERAPEUTICS, INC. a Delaware corporation (“Lessee”). IT IS HEREBY AGREED: Lessor hereby leases to Lessee, and Lessee hereby leases from Lessor, the premises described in Pa |
|
| March 13, 2017 |
Warrant Agreement with Hercules Technology III, L.P. dated March 7, 2017 EXHIBIT 4.3 THIS WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNS |
|
| March 13, 2017 |
Exhibit 10.25 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of March 7, 2017 and is entered into by and between AUDENTES THERAPEUTICS, INC., a Delaware corporation, and each of its Qualified Subsidiaries (hereinafter collectively referred to as the “Borrower”), the several banks and other financial institutions or entities from time to time parties to this Agree |
|
| March 10, 2017 |
Audentes Therapeutics 10-K (Annual Report) bold-10k20161231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001- |
|
| March 9, 2017 |
Audentes Therapeutics 8-K FY2016 EARNINGS RELEASE (Current Report/Significant Event) bold-8k20170309.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2017 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State or Other Jurisdiction of Inco |
|
| March 9, 2017 |
bold-ex9916.htm Exhibit 99.1 Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update - IND for AT132 to treat X-Linked Myotubular Myopathy (XLMTM) submitted - IND for AT342 to treat Crigler-Najjar Syndrome active - Large scale, internal cGMP manufacturing established to support advancement of pipeline programs - Preliminary clinical data from |
|
| March 7, 2017 |
EX-99.1 2 d355106dex991.htm EX-99.1 Exhibit 99.1 Audentes Corporate Overview Cowen and Company 37th Annual Health Care Conference March 7, 2017 Courageous Patients. Bold Effort. Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks |
|
| March 7, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2017 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Comm |
|
| February 14, 2017 |
BOLD / Audentes Therapeutics, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 14, 2017 |
BOLD / Audentes Therapeutics, Inc. / Versant Side Fund IV, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 05070R104 (CUSIP Number) December 31, 2016 (Date of Ev |
|
| February 14, 2017 |
BOLD / Audentes Therapeutics, Inc. / 5AM VENTURES III, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number) |
|
| February 13, 2017 |
BOLD / Audentes Therapeutics, Inc. / OrbiMed Capital GP IV LLC - 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 13, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2016 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Comm |
|
| November 29, 2016 |
EX-99.1 Courageous Patients. Bold Effort.? November 2016 Audentes Corporate Overview NASDAQ: BOLD Exhibit 99.1 AUDENTES THERAPEUTICS C 2 ORPORATE PRESENTATION Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, as |
|
| November 29, 2016 |
Audentes Therapeutics 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2016 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 ( |
|
| November 11, 2016 |
EX-99.1 2 bold-ex9917.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update Completed Initial Public Offering of 5.675 Million Shares of Common Stock, Completed Large-Scale Engineering Runs at Its Internal Manufacturing Facility, Commenced Enrollment in the INCEPTUS Clincal Assessment Study of XLMTM San Francisco, Calif., November |
|
| November 11, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 bold-8k20160930.htm 8-K Q3-16 RELEASE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2016 Audentes Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37833 46-1606174 (State o |
|
| November 10, 2016 |
Audentes Therapeutics 10-Q (Quarterly Report) bold-10q20160930.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2016 OR ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001 |
|
| September 28, 2016 |
EX-99.1 September 2016 Audentes Corporate Overview NASDAQ: BOLD Exhibit 99.1 Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actu |
|
| September 28, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2016 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Com |
|
| September 1, 2016 |
BOLD / Audentes Therapeutics, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2016 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-37833 Audentes Therapeuti |
|
| August 31, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2016 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37833 46-1606174 (Co |
|
| August 31, 2016 |
EX-99.1 2 d251485dex991.htm EX-99.1 Exhibit 99.1 Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update Achievements Included Completion of IPO, Initiation of Large Scale Manufacturing Runs and Enrollment of First Patient in a Clinical Assessment Study of XLMTM San Francisco, Calif., August 31, 2016 / PRNewswire/ — Audentes Therapeutics, Inc. (Nasdaq: BOL |
|
| July 27, 2016 |
BOLD / Audentes Therapeutics, Inc. / Sofinnova Venture Partners IX, L.P. - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Audentes Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 05070R104 (CUSIP Number) July 20, 2016 |
|
| July 25, 2016 |
BOLD / Audentes Therapeutics, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| July 20, 2016 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-208842 PROSPECTUS 5,000,000 Shares Common Stock This is Audentes Therapeutics, Inc.?s initial public offering. We are selling 5,000,000 shares of our common stock. The initial public offering price of our common stock is $15.00 per share. Our common stock has been approved for listing on The NASDAQ Global Market under th |
|
| July 20, 2016 |
As filed with the Securities and Exchange Commission on July 20, 2016 Registration No. |
|
| July 19, 2016 |
Unassociated Document Joint Filer Information Names: Deerfield Mgmt III, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P. Address: 780 Third Avenue, 37th Floor New York, NY 10017 Designated Filer: James E. Flynn Issuer and Ticker Symbol: Audentes Therapeutics, Inc. [BOLD] Date of Event Requiring Stateme |
|
| July 15, 2016 |
CORRESP July 15, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| July 15, 2016 |
CORRESP July 15, 2016 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Suzanne Hayes Scot Foley Amy Reischauer Tabatha McCullom Joel Parker Re: Audentes Therapeutics, Inc. Amendment No. 3 to Registration Statement on Form S-1 Filed July 11, 2016 File No. 333-208842 Ladies and Gentlemen: We are submitting this lette |
|
| July 15, 2016 |
CORRESP AUDENTES THERAPEUTICS, INC. 600 California Street, 17th Floor San Francisco, California 94108 July 15, 2016 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Suzanne Hayes Scot Foley Amy Reischauer Tabatha McCullom Joel Parker Re: Audentes Therapeutics, Inc. Registration Statement on Form S-1 (File |
|
| July 13, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF l934 Audentes Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-1606174 (State of incorporation or organization) (I.R.S. Employer Identification No.) 600 California S |
|
| July 11, 2016 |
2016 Equity Incentive Plan and forms of award agreements Exhibit 10.3 AUDENTES THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Co |
|
| July 11, 2016 |
As filed with the Securities and Exchange Commission on July 11, 2016 Amendment No. 3 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on July 11, 2016 Registration No. 333-208842 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AUDENTES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 2836 46-16 |
|
| July 11, 2016 |
Restated Certificate of Incorporation of the Registrant Exhibit 3.2 AUDENTES THERAPEUTICS, INC. RESTATED CERTIFICATE OF INCORPORATION Audentes Therapeutics, Inc., a Delaware corporation, hereby certifies as follows. 1. The name of the corporation is Audentes Therapeutics, Inc. The date of filing its original Certificate of Incorporation with the Secretary of State was November 13, 2012 under the name Audentes Therapeutics, Inc. 2. The Restated Certific |
